Latest News about NVS
Recent news which mentions NVS
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
January 30, 2023
From Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
From Benzinga
Could This Be Novartis' Next Blockbuster Medicine?
January 27, 2023
From Motley Fool
From Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
From InvestorPlace
From Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
January 19, 2023
From Benzinga
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
January 10, 2023
Tickers
NVS
From Benzinga
3 Biotech Companies to Watch in 2023
January 06, 2023
From InvestorPlace
2 Top Biotech Stocks to Buy Right Now
January 06, 2023
From Motley Fool
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
From Benzinga
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
From Motley Fool
From Benzinga
From Benzinga
5 Value Stocks In The Healthcare Sector
December 26, 2022
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 23, 2022
From Benzinga
3 Ridiculously Cheap Dividend Stocks That Yield More Than 3%
December 22, 2022
From Motley Fool
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
From Benzinga
From Benzinga
A Career Politician Who Regularly Trades The SPY, Picked Up There 3 High Yielding ETFs Instead
December 13, 2022
From Benzinga
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
December 12, 2022
From InvestorPlace
Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
December 09, 2022
From Benzinga
Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial
December 08, 2022
Tickers
NVS
From Benzinga
3 Hot Stocks That Could Live Up to Their Lofty Valuations
December 08, 2022
From Motley Fool
From Benzinga
Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo
December 07, 2022
Tickers
NVS
From Benzinga
Novartis prostate cancer drug trial meets primary endpoint
December 05, 2022
Tickers
NVS
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.